• 1
    De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS. Radioimmunoscintigraphy and biodistribution of 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995;1: 5918.
  • 2
    Stroomer JWG, Roos JC, Sproll M, Quak JJ, Heider K-H, Wilhelm AJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Van Dongen GAMS. Safety and biodistribution of 99mtechnetium-labeled anti-CD44v6 monoclonal antibody BIWA-1 in head and neck cancer patients. Clin Cancer Res 2000;6: 304655.
  • 3
    Van Hal NLW, Van Dongen GAMS, Rood-Knippels EMC, Van der Valk P, Snow GB, Brakenhoff RH. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a CD44 isoform. Int J Cancer 1996;68: 5207.
  • 4
    Heider K-H, Sproll M, Susani S, Patzelt E, Beaumier P, Ostermann E, Ahorn N, Adolf GR. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 1996;43: 24553.
  • 5
    Van Hal NLW, Van Dongen GAMS, Ten Brink CB, Heider K-H, Rech-Weichselbraun I, Snow GB, Brakenoff RH. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clin Cancer Res 1999;5: 353441.
  • 6
    Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993;54: 271335.
  • 7
    Webb DS, Shimizu Y, Van Seventer GA, Shaw S, Gerrard TL. LFA-3, CD44 and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 1990;249: 12957.
  • 8
    Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 1992;118: 9717.
  • 9
    Koopman G, Taher TE, Mazzucchelli I, Keehnen RM, Van der Voort R, Manten-Horst E, Ricevuti G, Pals ST, Das PK. CD44 isoforms, including the CD44v3 variant, are expressed on endothelium, suggesting a role for CD44 in the immobilization of growth factors and the regulation of local immune response. Biochem Biophys Res Commun 1998;7: 1726.
  • 10
    Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matsku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65: 1324.
  • 11
    Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, Herrlich P, Matsku S, Zoller M. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993;177: 44355.
  • 12
    Kaufmann M, Heider K-H, Sinn HP, Von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345: 6159.
  • 13
    Mulder JW, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GH, Pals ST. Colorectal cancer prognosis and expression of exon-v6–containing CD44 proteins. Lancet 1994;344: 14702.
  • 14
    Stauder R, Eistener W, Thaler J, Günther U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995;85: 288590.
  • 15
    Van Gog FB, Visser GWM, Klok R, Van der Schors R, Snow GB, Van Dongen GAMS. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelate groups and biodistribution characteristics. J Nucl Med 1996;37: 35262.
  • 16
    Khazaeli MB, Conry R, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994;15: 4252.
  • 17
    Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J. Radioimmunolocalization of human carcinoma xenografts with 72.3 second generation monoclonal antibodies. Cancer Res 1988;48: 4597603.
  • 18
    Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, Hinkle G, Siler K. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992;52: 106772.
  • 19
    Langmuir VK, Mendonca HL, Woo DV. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res 1992;52: 472834.
  • 20
    Kievit E, Pinedo HM, Schluper HM, Haisma HJ, Boven E. Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumor uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Br J Cancer 1996;73: 45764.
  • 21
    Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998;58: 48590.
  • 22
    Kugelman LC, Gangluly S, Haggerty JG, Weissman SM, Milstone LM. The core protein of epican, a heparan sulfate proteoglycan on keratinocytes, is an alternative form of CD44. J Invest Dermatol 1992;99: 88691.
  • 23
    Himmler A, Maurer-Fogy I, Kronke M, Scheurich P, Pfizenmaier K, Lantz M, Olssen I, Hauptmann R, Stratowa C, Adolf GR. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis binding protein. DNA Cell Biol 1990;9: 70515.
  • 24
    Haisma HJ, Hilgers J, Zurawski VR Jr. Iodination of monoclonal antibodies for diagnosis and therapy using a convenient one vial method. J Nucl Med 1986;27: 18905.
  • 25
    Sharkey RM, Natale A, Goldenberg DM, Mattes MJ. Rapid blood clearance of immunoglobulin G2a and immunoglobulin G2b in nude mice. Cancer Res 1991;51: 31027.
  • 26
    Van Gog FB, Brakenhoff RH, Snow GB, Van Dongen GAMS. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice. Cancer Immunol Immunother 1997;44: 10311.
  • 27
    Steffens MG, Kranenborg MH, Boerman OC, Zegwaart-Hagemeier NE, Debruyne FM, Corstens FH, Oosterwijk E. Tumor retention of 186Re-MAG3, 111In-DTPA and 125I-labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts. Cancer Biother Radiopharm 1998;13: 1339.
  • 28
    Kievit E, Van Gog FB, Schluper HM, Van Dongen GAMS, Pinedo HM, Boven E. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts. Int J Radiat Oncol Phys 1997;38: 81323.
  • 29
    Gallinger S, Reilly RM, Kirsh JC, Odze RD, Schmocker BJ, Hay K, Polihronis J, Damani MT, Shpitz B, Stern HS. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 1993;53: 2718.
  • 30
    Velders MP, Van Rhijn CM, Briaire IH, Fleuren GJ, Warnaar SO, Litvinov SV. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res 1995;55: 4398403.
  • 31
    Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 2001;61: 47505.
  • 32
    Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31: 11918.